Amarin Corp Plc (AMRN)

[Whalatane]

T. Its been awhile but the FDA refused to approve the Anchor indication ( TG's below 500 mg/dl ) because they felt patients would be using Vascepa this way to reduce CV event risk ...rather than risk of Pancreatitis ( TG's over 500 mg/dl ) .

So they forced AMRN to complete the R-IT trial to prove that Vascepa would reduce CV events

Kiwi